Questcor HP Acthar
Executive Summary
Questcor plans to ship HP Acthar gel in September following acquisition of the andrenocorticotropic hormone gel from Aventis. The National Organization for Rare Disorders has administered a patient access program for Acthar since 1996 due to limited availability of the product; Questcor expects to resume normal distribution of Acthar in the fall. Aventis will continue to manufacture Acthar for two to three years while production is transitioned to a new manufacturer. Acthar is approved for acute exacerbations of multiple sclerosis but is commonly used off-label to treat infantile spasms. Questcor will use its 19-rep sales force to promote Acthar to the approximately 900 pediatric neurologists in the U.S